Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Abstract: Provided are modifications of human interleukin-2 (IL-2) and interferon ? (IFN?), a fusion protein formed by modified IL-2, IFN? or both of IL-2/IFN? and an Fc, and design, preparation and use of the fusion protein. By changing the binding capacity of IFN? to a receptor thereof by means of gene mutation, a superior fusion protein is acquired, which may overcome the defects of weak specificity and serious adverse effects of existing drugs.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Abstract: A light emitting substrate has a functional area and a bonding area. The bonding area and the functional area are arranged along a first direction in sequence. The light-emitting substrate includes a substrate, a plurality of functional element groups, and a first electrostatic pathway. The plurality of functional element groups are located on a side of the substrate and located in the functional area. The first electrostatic pathway is located on a same side of the substrate with the plurality of functional element groups. The first electrostatic pathway is electrically connected to the bonding area, a portion of the first electrostatic pathway is located in the functional area, and the first electrostatic pathway is configured to conduct static electricity from the functional area to the bonding area.

Abstract: A light-emitting substrate includes a first substrate, a reflective layer and support columns. The reflective layer is disposed on the first substrate and provided with first openings. At least for two of cross-sections, parallel to a place where the first substrate is located, of a first opening, an area of a cross-section relatively proximate to the first substrate is less than an area of a cross-section relatively away from the first substrate. The support columns are located on a side of the reflective layer away from the first substrate and fixed on the first substrate. An orthographic projection of a support column on the first substrate is a first projection, an orthographic projection a minimum cross-section of the cross-sections is a second projection, and the second projection lies within a range of the first projection.

Abstract: A light emitting element includes a base substrate, light emitting structures on the base substrate, a filling layer among the light emitting structures, a connecting electrode layer, an insulating layer, and pads. The connecting electrode layer is located at a side, away from the base substrate, of the filling layer. The insulating layer is located at a side, away from the filling layer, of the connecting electrode layer. The pads are located at a side, away from the connecting electrode layer, of the insulating layer. Each light emitting structure includes a first pole and a second pole. The connecting electrode layer includes connecting electrodes each connected to the first pole or the second pole of at least one light emitting structure. The light emitting element further includes holes in the insulating layer. The pads are connected to the connecting electrodes through the holes.

Abstract: Provided are an array substrate and an electronic apparatus. The array substrate includes: a base substrate; a first conductive layer on the base substrate, where the first conductive layer includes a plurality of pads, each pad includes a first metal layer, a material of the first metal layer includes Cu, a content of the Cu is greater than or equal to 99%, and a thickness of the first metal layer is greater than 2 ?m; and an electronic element disposed on a side of the first conductive layer facing away from the base substrate, where the electronic element includes an electronic element body and a plurality of pins disposed on a side of the electronic element body facing the base substrate, and the pins are connected with the pads.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: The present application provides an array base plate and a light emitting apparatus, which relates to the technical field of displaying. The array base plate includes: a substrate; and a plurality of electrically-conductive-pad groups located on the substrate, wherein each of the electrically-conductive-pad groups includes at least one electrically conductive pad; the electrically conductive pad includes an electrically conducting layer and a first connecting layer, the first connecting layer is located on one side of the electrically conducting layer away from the substrate, and an orthographic projection of the first connecting layer on the substrate and an orthographic projection of the electrically conducting layer on the substrate at least partially intersect or overlap; and a thickness of the first connecting layer in a thickness direction of the substrate is greater than or equal to a thickness of the electrically conducting layer in the thickness direction of the substrate.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Abstract: The invention relates to a shared storage space access method, device and system and a storage medium. The product comprises a control module. The control module comprises an instruction cache unit, an instruction processing unit and a storage queue unit. The instruction caching unit is used for storing a calculation instruction associated with the artificial neural network operation; the instruction processing unit is used for analyzing the calculation instruction to obtain a plurality of operation instructions; the storage queue unit is used for storing an instruction queue, and the instruction queue comprises a plurality of operation instructions or calculation instructions to be executed according to the front-back sequence of the queue. Through the method or the product, the access efficiency of the storage space can be improved.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: The invention relates to a shared storage space access method, device and system and a storage medium. The product comprises a control module. The control module comprises an instruction cache unit, an instruction processing unit and a storage queue unit. The instruction caching unit is used for storing a calculation instruction associated with the artificial neural network operation; the instruction processing unit is used for analyzing the calculation instruction to obtain a plurality of operation instructions; the storage queue unit is used for storing an instruction queue, and the instruction queue comprises a plurality of operation instructions or calculation instructions to be executed according to the front-back sequence of the queue. Through the method or the product, the access efficiency of the storage space can be improved.

Abstract: A fusion protein, which is characterized in that the fusion protein is composed by interleukin-2 (IL-2) being fused with and linked to an anti-human epithelial cell adhesion molecule (EpCAM) single-chain antibody. Further provided by the present solution is a use of the fusion protein in the preparation of a drug for treating tumors.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.